Next Phase Newsletter

A venture capital firm based in Singapore makes early, growth, expansion, and mezzanine stage investments in the healthcare sector. The firm typically invests in the Series A and B rounds. The firm has raised two funds to date. The firm seeks to invest in non-Asian companies that are interested in entering the Asian market; investment funds are prioritized to companies looking to set up operations in Singapore. The firm will also invest in companies based in Asia. The investment size is variable depending on the stage of the company; ranging from $1M to $10M or more. The firm will consider opportunities from around the globe and is actively seeking new investment opportunities.

The firm seeks to invest in biopharmaceuticals, medical devices and digital health. For therapeutics, the firm prefers novel small molecules and biologics targeting indications in large markets. The firm prefers to invest in platform technologies and typically invests in clinical stage opportunities. For medical devices, the firm prefers devices in the later stages of development or near commercialization. In digital health, the firm looks for companies targeting wellness, chronic diseases and distributed care.

The firm seeks a strong management team and considers both private and public companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A leading medical technology company partners with companies from their formation through to commercialization, including expansion of operations and channel access.   The firm considers a variety of engagement models including research collaborations, licenses, investments and acquisition when partnering with companies aligned with their core businesses and new areas of strategic interest, seeking opportunities from around the globe.

The firm is currently seeking innovative companies working in sectors of medical technology, diagnostics, and healthcare IT. Within these areas, the firm is most interested in technologies including Information enabled devices, healthcare data analytics, parenteral delivery, patient and healthcare worker safety, microfluidics and point-of-care diagnostics, specimen collection and preservation, next generation sequencing, and developing world / maternal and newborn health. The firm considers opportunities in these areas on a case-by-case basis.

The firm prefers to partner with experienced management teams with a track record of accomplishment including graduates from respected accelerators and incubators, providing in-kind support to advance business plan development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Europe focuses solely on the life sciences. The firm recently closed their third fund and is actively looking for new investments, usually in series A & B rounds. Typically, the firm allocates €8M-€10M over the life of the investment with about half of that amount up front, in the initial investment. The firm primarily invests in companies that are based in Europe, but will also consider opportunities in North America.

The firm invests primarily in biotech therapeutics and medical devices. For biotech, the firm invests in pre-clinical up unto phase II assets. For medical devices, the firm prefers companies with with initial clinical proof-of-concept up unto reaching regulatory approval, whether that be PMA or 510(k) approval. The firm is somewhat less interested in diagnostic technologies. The firm is agnostic in terms of subsectors and indications, including orphan indications, but is very interested in products that address clear unmet opportunities. Historically, the firm invested in biotech therapeutics that address inflammatory, orphan, respiratory, autoimmune, infectious and cardiovascular disorders. Medical device investments have included a non-active implantable device for pulmonary embolism, as well as devices for renal and cardiovascular and peripheral vascular diseases.

The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A California-based VC firm raised its first fund in 2016. The firm invests in early stage healthcare technologies that are strategically relevant to its LPs, which are major healthcare corporations. The firm is a multi-stage investor, interested in companies from the seed stage through to late-stage venture rounds. Investments therefore vary by stage, but the firm’s Series A investments may typically be of about $1-3 million. The firm generally prefers to act as a co-investor, and is focused on US-based opportunities.

The firm is interested in new technologies in digital health, diagnostics, home care technology, and also therapeutics in musculoskeletal disease, respiratory disease and cardiovascular and metabolic diseases. The firm’s primary focus is on the intersection between data and biotech, diagnostics and medical devices, with microfluidics, connected devices, digitization, and automation being areas of high interest. For therapeutics, the firm generally does not invest in single-asset companies; therapeutic platform technologies that have the potential to create multiple ‘shots on goal’ are preferred. The firm prefers to focus on patients for whom there is high unmet need and no currently adequate treatments; rare diseases are of high interest. The firm is a multi-stage investor, and is open to investing in assets as early as the preclinical or pre-prototype stage.

The firm seeks management teams that display knowledge of how to build a business out of a strong technology. The firm focuses on technologies that allow the firm’s LPs to provide a value-add in partnering, manufacturing or distribution; healthcare technologies involving sensors and materials science are high focus areas. The firm evaluates opportunities on a technical, clinical and leadership level; the firm then shares the results of their diligence with the company in order to help the company in their future efforts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A medical technology venture firm based in Massachusetts makes equity investments in early stage companies developing products for to accelerate the trend of precision medicine diagnostics. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $5-15 M and is calibrated to milestone attainment. The firm is currently seeking opportunities around the world.

The firm focuses on three market segments that support knowledge-generating precision medicine diagnosis: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) diagnostic technologies that guide or are a companion to precision therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm based in Toronto, Canada is actively looking for new investments in the life science sector, especially medical technology. The firm’s current fund focuses on pre and post Series A investments with the ability to do follow-on funding. The investment size can range from $100K to over $1M and up to $2-4M with follow-on funding. The firm typically co-invests and will lead investments depending on the occasion and size of the round. Investment can be in form of equity, whereas convertible loan and other capital structures will be considered. The new fund looks to invest in 10-20 companies. The firm focuses on companies based in Canada, but it will also look at opportunities in the US.

In the life sciences, the firm is currently looking for new investments in the medical technology, diagnostics, and healthcare IT sectors with a particular interest in medical devices with a software component. The firm is interested in all classes of medical devices and is indication agnostic. The firm is focused on preclinical to clinical stage technology and is focused on technology that requires an FDA regulatory pathway. Thus, the firm is not interested in wearables or consumer connected devices. The firm will consider therapeutics companies from time-to-time, however, therapeutics is not the firm’s focus. Historically, the firm was active in a company developing blood-testing platform for infectious diseases.

The firm focuses on investments in private companies with an experienced management team and growth potential. The firm will take a board seat based on case-by-case basis, though is not the requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The venture capital subsidiary of a large healthcare corporation based in Europe invests to take minority stakes in innovative technology start-ups. The firm can lead or co-invest with other investors. Typical allocations are made in equity and range from €1-10 million. The firm is currently seeking new opportunities across a wide geography, including Western Europe, North and South America and Asia.

The firm focuses on medical devices and health IT products that present novel treatment, monitoring, or self-care strategies in home settings. In general, the firm is interested in chronic diseases, particularly in COPD, sleep apnea, renal diseases, and Parkinson’s disease. The technology should complement its current portfolio and fit the parent group’s long-term goals. The firm specializes in early stage projects from concept to clinical development.

The firm is looking for competent management teams with some previous experience in taking a company to an exit and understanding of the negotiations throughout the process. The firm typically takes a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com